Insurance Coverage Doesn't Guarantee Medication Access, SHARx Says

SHARx argues that medication access remains constrained despite coverage, citing prior authorization, step therapy, formulary exclusions, and specialty pharmacy restrictions that can delay or block treatment. The article cites national survey data showing 51% of insured adults sought prior authorization in the past two years and that insurer delays/denials are a major problem for 73%, alongside physician reports that prior authorization delays care (93%) and can lead patients to abandon treatment (82%). A case example highlights a rejected third-line therapy estimated at ~$10,000/month out of pocket, framing a material medical and financial risk to patients.

Analysis

The market mechanism here is not “coverage” but friction as a pricing lever. Prior authorization and specialty routing let payers suppress near-term claim spend, but the economic cost often resurfaces later as abandonment, higher-acuity utilization, and more appeals/admin overhead—good for short-term reported cost trend, bad for long-run MLR stability and employer satisfaction. The beneficiaries are the intermediaries that monetize complexity: specialty pharmacies, hub services, distribution/logistics, and mail-order channels that capture the rework around denied or delayed fills.

The immediate stock impact should be muted unless this turns into a rulemaking or litigation story. A credible 1-3 month catalyst would be CMS or state-level prior-auth standardization, especially deadline auto-approval or formulary transparency requirements; that would hit utilization-management leverage at UNH, CVS, ELV, and CI more than it would hit pure providers. If that regime shift happens, the second-order winner is COR and MCK, which can gain share as scripts migrate into channels that are built to manage high-friction specialty access.

Contrarian view: consensus tends to assume friction is “free” because the savings show up first in the payer P&L, but employers increasingly price in downstream productivity and catastrophic-care costs, so the political risk is asymmetric over 12-24 months. The overdone part is assuming this article alone is a catalyst; absent a regulatory trigger, it is mostly sentiment. For ADLI/HRDI specifically, there is no visible company-level monetization path from this theme, so treat them as watch items rather than conviction longs or shorts.

Key Decisions for Investors

• No direct trade in ADLI/HRDI: stay flat until there is company-specific evidence of exposure to prior-auth navigation, specialty fulfillment, or employer benefits administration.
• Relative-value idea: long COR / short UNH as a 6-12 month pair if prior-auth reform momentum builds; COR should benefit from higher specialty routing, while UNH faces modest margin pressure if denial leverage is reduced. Falsify on no CMS/state action by quarter-end.
• Alternative pair: long MCK / short CVS over 3-6 months if the market starts to price tighter utilization-management rules; MCK has cleaner leverage to distribution and specialty access, while CVS carries more regulatory and PBM optics risk.
• If a policy proposal lands, buy 1-2 month put spreads on ELV or CI rather than outright shorts; the initial move should be headline-driven, but the real risk is multiple compression from lower confidence in managed-care pricing power.
• Watch the catalyst, not the article: only act if CMS, a major state, or large employer coalitions move on standardized prior authorization deadlines; otherwise keep this on the monitor list.